메뉴 건너뛰기




Volumn 171, Issue 3, 2014, Pages 353-362

The impact of dipeptidyl peptidase 4 inhibition on incretin effect, glucose tolerance, and gastrointestinal-mediated glucose disposal in healthy subjects

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INCRETIN; PARACETAMOL; SITAGLIPTIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR;

EID: 84907189229     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-14-0314     Document Type: Article
Times cited : (28)

References (37)
  • 1
    • 0029765475 scopus 로고    scopus 로고
    • Secretion of the incretin hormones glucagon-like peptide-1 and gastric inhibitory polypeptide correlates with insulin secretion in normalman throughout the day
    • Ørskov C, Wettergren A & Holst JJ. Secretion of the incretin hormones glucagon-like peptide-1 and gastric inhibitory polypeptide correlates with insulin secretion in normalman throughout the day. Scandinavian Journal of Gasteroenterology 1996 31 665-670. (doi:10.3109/00365529609009147)
    • (1996) Scandinavian Journal of Gasteroenterology , vol.31 , pp. 665-670
    • Ørskov, C.1    Wettergren, A.2    Holst, J.J.3
  • 2
    • 0031916924 scopus 로고    scopus 로고
    • Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig
    • Deacon CF, Hughes TE & Holst JJ. Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig. Diabetes 1998 47 764-769. (doi:10.2337/diabetes.47. 5.764)
    • (1998) Diabetes , vol.47 , pp. 764-769
    • Deacon, C.F.1    Hughes, T.E.2    Holst, J.J.3
  • 3
    • 0027419106 scopus 로고
    • Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at nearphysiological insulinotropic hormone and glucose concentrations
    • Nauck MA, Bartels E, Ørskov C, Ebert R & Creutzfeldt W. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at nearphysiological insulinotropic hormone and glucose concentrations. Journal of Clinical Endocrinology and Metabolism 1993 76 912-917. (doi:10.1210/jcem.76.4.8473405)
    • (1993) Journal of Clinical Endocrinology and Metabolism , vol.76 , pp. 912-917
    • Nauck, M.A.1    Bartels, E.2    Ørskov, C.3    Ebert, R.4    Creutzfeldt, W.5
  • 4
    • 79953871128 scopus 로고    scopus 로고
    • Inhibition of DPP-4 with vildagliptin improved insulin secretion in response to oral as well as "isoglycemic" intravenous glucose without numerically changing the incretin effect in patients with type 2 diabetes
    • Vardarli I, Nauck MA, Köthe LD, Deacon CF, Holst JJ, Schweizer A & Foley JE. Inhibition of DPP-4 with vildagliptin improved insulin secretion in response to oral as well as "isoglycemic" intravenous glucose without numerically changing the incretin effect in patients with type 2 diabetes. Journal of Clinical Endocrinology and Metabolism 2011 96 945-954. (doi:10.1210/jc.2010-2178)
    • (2011) Journal of Clinical Endocrinology and Metabolism , vol.96 , pp. 945-954
    • Vardarli, I.1    Nauck, M.A.2    Köthe, L.D.3    Deacon, C.F.4    Holst, J.J.5    Schweizer, A.6    Foley, J.E.7
  • 5
    • 84893035432 scopus 로고    scopus 로고
    • Effects of sitagliptin and metformin treatment on incretin hormone and insulin secretory responses to oral and "isoglycemic" intravenous glucose
    • Vardarli I, Arndt E, Deacon CF, Holst JJ & Nauck MA. Effects of sitagliptin and metformin treatment on incretin hormone and insulin secretory responses to oral and "isoglycemic" intravenous glucose. Diabetes 2014 63 663-674. (doi:10.2337/db13-0805)
    • (2014) Diabetes , vol.63 , pp. 663-674
    • Vardarli, I.1    Arndt, E.2    Deacon, C.F.3    Holst, J.J.4    Nauck, M.A.5
  • 7
    • 84903517797 scopus 로고    scopus 로고
    • Incretin effect and glucagon responses to oral and intravenous glucose in patients with maturity onset diabetes of the young - Type 2 and type 3
    • In Press
    • Østoft SH, Bagger JI, Hansen T, Pedersen O, Holst JJ, Knop FK & Vilsbøll T. Incretin effect and glucagon responses to oral and intravenous glucose in patients with maturity onset diabetes of the young - type 2 and type 3. Diabetes 2014. In Press. (doi:10.2337/db13-1878)
    • (2014) Diabetes
    • Østoft, S.H.1    Bagger, J.I.2    Hansen, T.3    Pedersen, O.4    Holst, J.J.5    Knop, F.K.6    Vilsbøll, T.7
  • 8
    • 0018760491 scopus 로고
    • Simultaneous measurements of acetaminophen and salicylate in plasma by liquid chromatography
    • Miceli JN, Aravind MK, Cohen SN & Done AK. Simultaneous measurements of acetaminophen and salicylate in plasma by liquid chromatography. Clinical Chemistry 1979 25 1002-1004.
    • (1979) Clinical Chemistry , vol.25 , pp. 1002-1004
    • Miceli, J.N.1    Aravind, M.K.2    Cohen, S.N.3    Done, A.K.4
  • 9
    • 0035008133 scopus 로고    scopus 로고
    • Gastric emptying: The validity of the paracetamol absorption test adjusted for individual pharmacokinetics
    • Medhus AW, Lofthus CM, Bredesen J & Husebye E. Gastric emptying: the validity of the paracetamol absorption test adjusted for individual pharmacokinetics. Neurogastroenterology and Motility 2001 13 179-185. (doi:10.1046/j.1365-2982.2001.00249.x)
    • (2001) Neurogastroenterology and Motility , vol.13 , pp. 179-185
    • Medhus, A.W.1    Lofthus, C.M.2    Bredesen, J.3    Husebye, E.4
  • 10
    • 0028281773 scopus 로고
    • Tissue and plasma concentrations of amidated and glycine-extended glucagonlike peptide i in humans
    • Ørskov C, Rabenhøj L, Wettergren A, Kofod H & Holst JJ. Tissue and plasma concentrations of amidated and glycine-extended glucagonlike peptide I in humans. Diabetes 1994 43 535-539. (doi:10.2337/diab. 43.4.535)
    • (1994) Diabetes , vol.43 , pp. 535-539
    • Ørskov, C.1    Rabenhøj, L.2    Wettergren, A.3    Kofod, H.4    Holst, J.J.5
  • 11
    • 0021211623 scopus 로고
    • The heterogeneity of gastric inhibitory polypeptide in porcine and human gastrointestinal mucosa evaluated with five different antisera
    • Krarup T & Holst JJ. The heterogeneity of gastric inhibitory polypeptide in porcine and human gastrointestinal mucosa evaluated with five different antisera. Regulatory Peptides 1984 9 35-46. (doi:10.1016/0167-0115(84)90005-3)
    • (1984) Regulatory Peptides , vol.9 , pp. 35-46
    • Krarup, T.1    Holst, J.J.2
  • 12
    • 0033766716 scopus 로고    scopus 로고
    • Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide
    • Deacon CF, Nauck MA, Meier J, Hucking K & Holst JJ. Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. Journal of Clinical Endocrinology and Metabolism 2000 85 3575-3581. (doi:10.1210/jcem.85.10.6855)
    • (2000) Journal of Clinical Endocrinology and Metabolism , vol.85 , pp. 3575-3581
    • Deacon, C.F.1    Nauck, M.A.2    Meier, J.3    Hucking, K.4    Holst, J.J.5
  • 13
    • 4244188766 scopus 로고    scopus 로고
    • New highly specific immunoassays for glucagon-like peptide-1 (GLP-1) (Abstract)
    • Wilken M, Larsen F, Buckley D & Holst J. New highly specific immunoassays for glucagon-like peptide-1 (GLP-1) (Abstract). Diabetologia 1999 42 (Suppl 1) A196.
    • (1999) Diabetologia , vol.42 , pp. A196
    • Wilken, M.1    Larsen, F.2    Buckley, D.3    Holst, J.4
  • 14
    • 0026027919 scopus 로고
    • Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine
    • Ørskov C, Jeppesen J, Madsbad S & Holst JJ. Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine. Journal of Clinical Investigation 1991 87 415-423. (doi:10.1172/JCI115012)
    • (1991) Journal of Clinical Investigation , vol.87 , pp. 415-423
    • Ørskov, C.1    Jeppesen, J.2    Madsbad, S.3    Holst, J.J.4
  • 15
    • 0026504160 scopus 로고
    • Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance
    • Van Cauter E, Mestrez F, Sturis J & Polonsky KS. Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance. Diabetes 1992 41 368-377. (doi:10.2337/diabetes.41.3.368)
    • (1992) Diabetes , vol.41 , pp. 368-377
    • Van Cauter, E.1    Mestrez, F.2    Sturis, J.3    Polonsky, K.S.4
  • 17
    • 77949822066 scopus 로고    scopus 로고
    • Inappropriate glucagon response after oral compared with isoglycemic intravenous glucose administration in patients with type 1 diabetes
    • Hare KJ, Vilsbøll T, Holst JJ & Knop FK. Inappropriate glucagon response after oral compared with isoglycemic intravenous glucose administration in patients with type 1 diabetes. American Journal of Physiology. Endocrinology and Metabolism 2010 298 E832-E837. (doi:10.1152/ajpendo.00700.2009)
    • (2010) American Journal of Physiology. Endocrinology and Metabolism , vol.298 , pp. E832-E837
    • Hare, K.J.1    Vilsbøll, T.2    Holst, J.J.3    Knop, F.K.4
  • 18
    • 84899091067 scopus 로고    scopus 로고
    • Dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes treated with saxagliptin, sitagliptin, or vildagliptin
    • Tatosian DA, Guo Y, Schaeffer AK, Gaibu N, Popa S, Stoch A, Langdon RB & Kauh EA. Dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes treated with saxagliptin, sitagliptin, or vildagliptin. Diabetes Therapy 2013 4 431-442. (doi:10.1007/s13300-013-0045-8)
    • (2013) Diabetes Therapy , vol.4 , pp. 431-442
    • Tatosian, D.A.1    Guo, Y.2    Schaeffer, A.K.3    Gaibu, N.4    Popa, S.5    Stoch, A.6    Langdon, R.B.7    Kauh, E.A.8
  • 19
    • 33749871472 scopus 로고    scopus 로고
    • Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes
    • Herman GA, Bergman A, Stevens C, Kotey P, Yi B, Zhao P, Dietrich B, Golor G, Schrodter A, Keymeulen B et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. Journal of Clinical Endocrinology and Metabolism 2006 91 4612-4619. (doi:10.1210/jc.2006-1009)
    • (2006) Journal of Clinical Endocrinology and Metabolism , vol.91 , pp. 4612-4619
    • Herman, G.A.1    Bergman, A.2    Stevens, C.3    Kotey, P.4    Yi, B.5    Zhao, P.6    Dietrich, B.7    Golor, G.8    Schrodter, A.9    Keymeulen, B.10
  • 20
    • 35948941910 scopus 로고    scopus 로고
    • The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion
    • El-Ouaghlidi A, Rehring E, Holst JJ, Schweizer A, Foley J, Holmes D & Nauck MA. The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion. Journal of Clinical Endocrinology and Metabolism 2007 92 4165-4171. (doi:10.1210/jc.2006-1932)
    • (2007) Journal of Clinical Endocrinology and Metabolism , vol.92 , pp. 4165-4171
    • El-Ouaghlidi, A.1    Rehring, E.2    Holst, J.J.3    Schweizer, A.4    Foley, J.5    Holmes, D.6    Nauck, M.A.7
  • 22
    • 0036188070 scopus 로고    scopus 로고
    • Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs
    • Deacon CF, Wamberg S, Bie P, Hughes TE & Holst JJ. Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs. Journal of Endocrinology 2002 172 355-362. (doi:10.1677/joe.0.1720355)
    • (2002) Journal of Endocrinology , vol.172 , pp. 355-362
    • Deacon, C.F.1    Wamberg, S.2    Bie, P.3    Hughes, T.E.4    Holst, J.J.5
  • 25
    • 77954866977 scopus 로고    scopus 로고
    • The effect of DPP-4 inhibition with sitagliptin on incretin secretion and on fasting and postprandial glucose turnover in subjects with impaired fasting glucose
    • Bock G, Dalla Man C, Micheletto F, Basu R, Giesler PD, Laugen J, Deacon CF, Holst JJ, Toffolo G, Cobelli C et al. The effect of DPP-4 inhibition with sitagliptin on incretin secretion and on fasting and postprandial glucose turnover in subjects with impaired fasting glucose. Clinical Endocrinology 2010 73 189-196. (doi:10.1111/j.1365-2265.2009.03764.x)
    • (2010) Clinical Endocrinology , vol.73 , pp. 189-196
    • Bock, G.1    Dalla Man, C.2    Micheletto, F.3    Basu, R.4    Giesler, P.D.5    Laugen, J.6    Deacon, C.F.7    Holst, J.J.8    Toffolo, G.9    Cobelli, C.10
  • 26
    • 38149096290 scopus 로고    scopus 로고
    • Effects of the dipeptidyl peptidase- IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance
    • Rosenstock J, Foley JE, Rendell M, Landin-Olsson M, Holst JJ, Deacon CF, Rochotte E & Baron MA. Effects of the dipeptidyl peptidase- IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care 2008 31 30-35. (doi:10.2337/dc07-1616)
    • (2008) Diabetes Care , vol.31 , pp. 30-35
    • Rosenstock, J.1    Foley, J.E.2    Rendell, M.3    Landin-Olsson, M.4    Holst, J.J.5    Deacon, C.F.6    Rochotte, E.7    Baron, M.A.8
  • 27
    • 84877600473 scopus 로고    scopus 로고
    • Glucose-lowering effect of the DPP-4 inhibitor sitagliptin after glucose and non-glucose macronutrient ingestion in non-diabetic subjects
    • Ohlsson L, Alsalim W, Carr RD, Tura A, Pacini G, Mari A & Ahren B. Glucose-lowering effect of the DPP-4 inhibitor sitagliptin after glucose and non-glucose macronutrient ingestion in non-diabetic subjects. Diabetes, Obesity & Metabolism 2013 15 531-537. (doi:10.1111/dom. 12062)
    • (2013) Diabetes, Obesity & Metabolism , vol.15 , pp. 531-537
    • Ohlsson, L.1    Alsalim, W.2    Carr, R.D.3    Tura, A.4    Pacini, G.5    Mari, A.6    Ahren, B.7
  • 28
    • 77957741412 scopus 로고    scopus 로고
    • Effects of miglitol, sitagliptin or their combination on plasma glucose, insulin and incretin levels in non-diabetic men
    • Aoki K, Masuda K, Miyazaki T, Togashi Y & Terauchi Y. Effects of miglitol, sitagliptin or their combination on plasma glucose, insulin and incretin levels in non-diabetic men. Endocrine Journal 2010 57 667-672. (doi:10.1507/endocrj.K10E-103)
    • (2010) Endocrine Journal , vol.57 , pp. 667-672
    • Aoki, K.1    Masuda, K.2    Miyazaki, T.3    Togashi, Y.4    Terauchi, Y.5
  • 29
    • 84897445343 scopus 로고    scopus 로고
    • Effects of miglitol, vildagliptin, or their combination on serum insulin and peptide YY levels and plasma glucose, cholecystokinin, ghrelin, and obestatin levels
    • Aoki K, Kamiyama H, Masuda K, Kamiko K, Noguchi Y, Tajima K & Terauchi Y. Effects of miglitol, vildagliptin, or their combination on serum insulin and peptide YY levels and plasma glucose, cholecystokinin, ghrelin, and obestatin levels. Endocrine Journal 2014 61 249-256. (doi:10.1507/endocrj.EJ13-0399)
    • (2014) Endocrine Journal , vol.61 , pp. 249-256
    • Aoki, K.1    Kamiyama, H.2    Masuda, K.3    Kamiko, K.4    Noguchi, Y.5    Tajima, K.6    Terauchi, Y.7
  • 30
    • 84905019254 scopus 로고    scopus 로고
    • Effects of sitagliptin on glycemia, incretin hormones, and antropyloroduodenal motility in response to intraduodenal glucose infusion in healthy lean and obese humans, and patients with type 2 diabetes treated with or without metformin
    • In press
    • Wu T, Ma J, Bound MJ, Checklin H, Deacon CF, Jones KL, HorowitzM& Rayner CK. Effects of sitagliptin on glycemia, incretin hormones, and antropyloroduodenal motility in response to intraduodenal glucose infusion in healthy lean and obese humans, and patients with type 2 diabetes treated with or without metformin. Diabetes 2014. In press. (doi:10.2337/db13-1627)
    • (2014) Diabetes
    • Wu, T.1    Ma, J.2    Bound, M.J.3    Checklin, H.4    Deacon, C.F.5    Jones, K.L.6    Horowitz, M.7    Rayner, C.K.8
  • 31
    • 0027391607 scopus 로고
    • Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus
    • Nauck MA, Heimesaat MM, Ørskov C, Holst JJ, Ebert R & CreutzfeldtW. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. Journal of Clinical Investigation 1993 91 301-307. (doi:10.1172/JCI116186)
    • (1993) Journal of Clinical Investigation , vol.91 , pp. 301-307
    • Nauck, M.A.1    Heimesaat, M.M.2    Ørskov, C.3    Holst, J.J.4    Ebert, R.5    Creutzfeldt, W.6
  • 33
    • 82255185915 scopus 로고    scopus 로고
    • Glucose-dependent insulinotropic polypeptide: A bifunctional glucosedependent regulator of glucagon and insulin secretion in humans
    • Christensen M, Vedtofte L, Holst JJ, Vilsboll T & Knop FK. Glucose-dependent insulinotropic polypeptide: a bifunctional glucosedependent regulator of glucagon and insulin secretion in humans. Diabetes 2011 60 3103-3109. (doi:10.2337/db11-0979)
    • (2011) Diabetes , vol.60 , pp. 3103-3109
    • Christensen, M.1    Vedtofte, L.2    Holst, J.J.3    Vilsboll, T.4    Knop, F.K.5
  • 34
    • 0038121744 scopus 로고    scopus 로고
    • Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects
    • Vilsbøll T, Krarup T, Madsbad S & Holst JJ. Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects. Regulatory Peptides 2003 114 115-121. (doi:10.1016/S0167- 0115(03)00111-3)
    • (2003) Regulatory Peptides , vol.114 , pp. 115-121
    • Vilsbøll, T.1    Krarup, T.2    Madsbad, S.3    Holst, J.J.4
  • 35
    • 0037207057 scopus 로고    scopus 로고
    • The effects of duodenal peptides on glucagon-like peptide-1 secretion from the ileum
    • Hansen L & Holst JJ. The effects of duodenal peptides on glucagon-like peptide-1 secretion from the ileum. A duodeno-ileal loop? Regulatory Peptides 2002 110 39-45. (doi:10.1016/S0167-0115(02)00157-X)
    • (2002) A Duodeno-ileal Loop? Regulatory Peptides , vol.110 , pp. 39-45
    • Hansen, L.1    Holst, J.J.2
  • 36
    • 84867581999 scopus 로고    scopus 로고
    • Somatostatin receptor 5 and cannabinoid receptor 1 activation inhibit secretion of glucosedependent insulinotropic polypeptide from intestinal K cells in rodents
    • Moss CE, Marsh WJ, Parker HE, Ogunnowo-Bada E, Riches CH, Habib AM, Evans ML, Gribble FM & Reimann F. Somatostatin receptor 5 and cannabinoid receptor 1 activation inhibit secretion of glucosedependent insulinotropic polypeptide from intestinal K cells in rodents. Diabetologia 2012 55 3094-3103. (doi:10.1007/s00125-012- 2663-5)
    • (2012) Diabetologia , vol.55 , pp. 3094-3103
    • Moss, C.E.1    Marsh, W.J.2    Parker, H.E.3    Ogunnowo-Bada, E.4    Riches, C.H.5    Habib, A.M.6    Evans, M.L.7    Gribble, F.M.8    Reimann, F.9


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.